Betagan®
Levobunolol 0.5% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in chronic open-angle glaucoma or ocular hypertension
1 to 2 drops of 0.5% in the affected eye(s) QD; BID in more severe or uncontrolled glaucoma
IOP falls within 1 hour, peaks at 2 to 6 hours, lasts 24 hours, and averages a 7 to 8 mmHg drop.
Elevated IOP in chronic open-angle glaucoma or ocular hypertension, once-daily starting dose
One to two drops of 0.5% in the affected eye(s) once a day
Once-daily dosing gives a 14% to 18% IOP reduction, matching twice-daily by 2 weeks.
Contraindications
- Bronchial asthma or a history of bronchial asthma.
- Severe chronic obstructive pulmonary disease.
- Sinus bradycardia.
- Second and third degree atrioventricular block.
- Overt cardiac failure.
- Cardiogenic shock.
- Hypersensitivity to any component.
0.5% solution, 5 mL, 10 mL, 15 mL
Noncardioselective beta-adrenoceptor blocker, equipotent at beta-1 and beta-2 receptors, without significant intrinsic sympathomimetic or membrane-stabilizing activity. Lowers IOP most likely by decreasing aqueous humor production, with onset detectable within 1 hour, maximum effect at 2 to 6 hours, and a significant decrease that can be maintained for up to 24 hours after a single dose.
Warnings & Precautions
- Severe respiratory and cardiac reactions: Levobunolol may be absorbed systemically, and the same adverse reactions found with systemic beta-blockers may occur with topical administration. Severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported with topical beta-blockers. Ophthalmic beta-blockers may also impair compensatory tachycardia and increase risk of hypotension.
- Cardiac failure: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. Discontinue at the first sign or symptom of cardiac failure.
- Obstructive pulmonary disease: Patients with chronic obstructive pulmonary disease of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which levobunolol is contraindicated) should in general not receive beta blockers; if deemed necessary, administer cautiously, since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta 2 receptors.
- Vascular insufficiency: May potentiate syndromes associated with vascular insufficiency (i.e. Raynaud's phenomenon), and therefore should be used with caution in these patients.
- Cerebrovascular insufficiency: Because of potential effects on blood pressure and pulse rates, use cautiously in patients with cerebrovascular insufficiency; consider alternative therapy if signs or symptoms suggesting reduced cerebral blood flow develop.
- Major surgery: Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli, which may augment the risk of general anesthesia. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe hypotension during anesthesia, and difficulty in restarting and maintaining the heartbeat has also been reported, so gradual withdrawal before elective surgery may be appropriate.
- Diabetes mellitus: Use with caution in patients subject to spontaneous hypoglycemia or in diabetic patients (especially those with labile diabetes) receiving insulin or oral hypoglycemic agents; beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycemia.
- Thyrotoxicosis: Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism; manage suspected thyrotoxicosis carefully to avoid abrupt withdrawal, which might precipitate a thyroid storm.
- Muscle weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis and generalized weakness).
- Risk of anaphylactic reaction: While taking beta-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated challenge and may be unresponsive to the usual doses of epinephrine.
- Angle-closure glaucoma: Little or no effect on the pupil; when used to reduce elevated IOP in angle-closure glaucoma it should be followed with a miotic and not used alone.
- Choroidal detachment: Reported with aqueous suppressant therapy after filtration procedures.
- Sulfite sensitivity: Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people; sulfite sensitivity is seen more frequently in asthmatic people.
- Soft contact lenses: Benzalkonium chloride may be absorbed by soft lenses; remove lenses before instillation and wait at least 15 minutes before reinserting them.
- Hypersensitivity and pulmonary function: Use with caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents and in patients with known diminished pulmonary function.
- Additive beta-blockade: Use with caution in patients receiving an oral beta-adrenergic blocking agent because of potential additive effects on systemic beta-blockade or on intraocular pressure; patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
- Mydriasis: Although levobunolol used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with epinephrine may occur.
- Hypotension and marked bradycardia: Closely observe patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension; phenothiazine-related compounds may also have additive hypotensive effects.
- Atrioventricular conduction disturbances: Monitor patients also receiving oral or intravenous calcium antagonists for possible atrioventricular conduction disturbances, left ventricular failure and hypotension, and avoid simultaneous use in impaired cardiac function; digitalis with calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
Common Side Effects
Transient ocular burning and stinging occurs in up to 1 in 3 patients and blepharoconjunctivitis in up to 1 in 20 patients. Decreases in heart rate and blood pressure have been reported. Iridocyclitis, headache, transient ataxia, dizziness, lethargy, urticaria, and pruritus have been reported rarely, and decreased corneal sensitivity has been noted in a small number of patients. Reactions reported either with levobunolol or with ophthalmic use of other beta-adrenergic receptor blocking agents include bradycardia, arrhythmia, heart block, hypotension, syncope, congestive heart failure, cardiac arrest, bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, depression, and Stevens-Johnson Syndrome.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk. Fetotoxicity (increased resorption sites) occurred in rabbits at 200 and 700 times the recommended glaucoma dose, with no fetotoxicity or malformations in rats up to 1,800 times.
Lactation: Excretion in human milk is unknown, but systemic beta-blockers and topical timolol are excreted in human milk; use caution in a nursing woman.
Safety and effectiveness in pediatric patients have not been established.